HAT1 and neoplasm: In agreement with the effect on tumor regression, treatment with the anti-PD-1-antibody after the knockdown of Hat1 led to a further decrease in tumor growth and an increase in CD45+CD8+ and CD45+CD4+ T cell infiltration, but a greater decrease in CD11b+Gr1+ myeloid cells in tumors (Fig. 5f).